TIM3 Antikörper

Produktnummer ABIN2664620

Dieses Anti-TIM3-Antikörper ist ein Maus Monoklonal-Antikörper zur Detektion von TIM3 in WB, IHC, IF und ICFC. Geeignet für Human.

Kurzübersicht für TIM3 Antikörper (ABIN2664620)

Target: TIM3 (TIM 3) (Hepatitis A Virus Cellular Receptor 2 (TIM 3))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser TIM3 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), Intracellular Flow Cytometry (ICFC)

Klon: F38-2E2

Produktdetails anti-TIM3 Antikörper

Kreuzreaktivität: Rhesusaffen

Aufreinigung: The antibody was purified by affinity chromatography.

Isotyp: IgG1 kappa

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: The antibody solution should be stored undiluted between 2°C and 8°C.

Details zu TIM3

Target: TIM3 (TIM 3) (Hepatitis A Virus Cellular Receptor 2 (TIM 3))

Andere Bezeichnung: CD366

Substanzklasse: Virus

Hintergrund: CD366 (Tim-3) is a transmembrane protein also known as T cell immunoglobulin and mucin domain containing protein-3. Tim-3 is expressed at high levels on activated T cells (preferentially on Th1 cells, monocytes/macrophages, and dendritic cells). Tim-3 has also been shown to exist as a soluble protein. Cells expressing Tim-3 are present at high levels in the CNS of animals at the onset of experimental autoimmune encephalomyelitis (EAE), a disease mediated by lymphocytes secreting Th1-like cytokines. Tim-3 has been proposed to inhibit Th1-mediated immune responses and promote immunological tolerance.

Pathways: Regulation of Lipid Metabolism by PPARalpha, Cancer Immune Checkpoints